Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
164 participants
OBSERVATIONAL
2007-02-28
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
NCT00370331
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT01098487
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
NCT02158936
Eltrombopag for Inherited Thrombocytopenias
NCT02422394
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
NCT00359463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational
Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
Eltrombopag
Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eltrombopag
Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has signed and dated a written informed consent for this study.
* Subject has previously participated in a study evaluating eltrombopag, either phase II or III, and must have received at least one dose of study medication (either active drug or placebo). This excludes subjects from phase I studies (See Section 5.1).
* The prescribed follow-up ophthalmic assessment at 6 months post end of treatment should be completed as specified in the protocol for the previous study.
* Subject is able to understand and comply with protocol requirements and instructions.
Exclusion Criteria
* Subject has received surgery for cataracts and is aphakic or bilaterally pseudophakic.
* In some countries (i.e. France), a subject is neither affiliated with nor a beneficiary of a social security category.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Detroit, Michigan, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Kogarah, New South Wales, Australia
GSK Investigational Site
Plovdiv, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Caen, , France
GSK Investigational Site
Clichy, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Pessac, , France
GSK Investigational Site
Rouen, , France
GSK Investigational Site
Vandœuvre-lès-Nancy, , France
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Shatin, New Territories, , Hong Kong
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Chennai, , India
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Mumbai, , India
GSK Investigational Site
San Giovanni Rotondo, Apulia, Italy
GSK Investigational Site
Avellino, Campania, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Genoa, Liguria, Italy
GSK Investigational Site
Brescia, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Karachi, , Pakistan
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Samara, , Russia
GSK Investigational Site
St'Petersburg, , Russia
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
San Sebastián, , Spain
GSK Investigational Site
Santa Cruz de Tenerife, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Stockholm, , Sweden
GSK Investigational Site
Stockholm, , Sweden
GSK Investigational Site
Montfleury, , Tunisia
GSK Investigational Site
Sfax, , Tunisia
GSK Investigational Site
Sousse, , Tunisia
GSK Investigational Site
Tunis, , Tunisia
GSK Investigational Site
Dnipropetrovsk, , Ukraine
GSK Investigational Site
Donetsk, , Ukraine
GSK Investigational Site
Kyiv, , Ukraine
GSK Investigational Site
Vinnytsia, , Ukraine
GSK Investigational Site
Plymouth, Devon, United Kingdom
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Morriston, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRA108132
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.